Idera Pharmaceuticals
Idera Pharmaceuticals is a publicly traded Cambridge, MA-based clinical-stage biopharmaceutical company developing synthetic DNA and RNA-based drug candidates, with a pipeline reshaped by its 2022 acquisition of Aceragen and a focus on rare diseases.
- Company typePrivate
- Founded1989
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Idera Pharmaceuticals firmographics
Firmographics- Name
- Idera Pharmaceuticals
- Website
- https://iderapharma.com
- Company type
- Private
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Idera Pharmaceuticals is a publicly traded Cambridge, MA-based clinical-stage biopharmaceutical company developing synthetic DNA and RNA-based drug candidates, with a pipeline reshaped by its 2022 acquisition of Aceragen and a focus on rare diseases.
- Ownership category
- akta.pro rank
Idera Pharmaceuticals industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)
- akta.pro secondary industry
- Rare Dermatology Disorder Therapies (HLAIAIAM)
Keywords
Where Idera Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Idera Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Idera Pharmaceuticals product offering
Product offeringCore offering
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA- and RNA-based drug candidates. The company focuses on therapeutic applications in immune-mediated and rare diseases, and has expanded its rare-disease pipeline through its acquisition of Aceragen in 2022.
Differentiator
Problem solved
Functional benefit
Products and services
- Synthetic DNA- and RNA-based drug candidates
- Aceragen rare-disease pipeline assets
Companies that use Idera Pharmaceuticals
Customer profileIdeal customer profiles1 record
Idera Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Idera Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Wave Life Sciences: Clinical-stage nucleic-acid therapeutics company developing stereopure oligonucleotides. Directly comparable to Idera's synthetic DNA/RNA-based drug discovery platform.
- ProQR Therapeutics: Clinical-stage RNA therapeutics company developing Axiomer RNA-editing technology for rare genetic diseases. Directly comparable as an RNA-based rare-disease drug developer.
- Aceragen: The rare-disease biopharma that Idera acquired in September 2022 and effectively merged into. Directly comparable because its dermatomyositis and rare-disease pipeline is now the core of the combined company's strategy.
Broad incumbents
- Argenx: Commercial-stage immunology biopharma developing antibody therapies for rare autoimmune diseases including dermatomyositis. Comparable as a rare-autoimmune/dermatology-focused peer with validated commercial execution.
- Translate Bio (now Sanofi): mRNA therapeutics developer that was acquired by Sanofi. Comparable as an RNA-medicine platform company targeting rare and serious diseases.
Emerging players
- Corbus Pharmaceuticals: Clinical-stage biopharma developing treatments for rare autoimmune and inflammatory diseases. Comparable due to similar small-cap, rare-autoimmune clinical-stage profile.
- Kezar Life Sciences: Clinical-stage biotech focused on immunology and autoimmune diseases, including dermatomyositis. Comparable as a small-cap rare-autoimmune peer with overlapping therapeutic focus.
- Dyne Therapeutics: Clinical-stage biotech developing oligonucleotide therapeutics for rare muscle diseases. Comparable due to nucleic-acid modality and rare-disease focus.
- Caballeta Bio: Clinical-stage biotech developing cell therapies for autoimmune diseases including dermatomyositis. Comparable as an emerging player targeting the same rare autoimmune dermatology indications.
- Avidity Biosciences: Clinical-stage biotech developing antibody-RNA conjugates for rare neuromuscular diseases. Comparable as a nucleic-acid rare-disease therapeutics developer.
Market position
Customer concentration
Idera Pharmaceuticals social profiles
Digital presenceIdera Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Idera Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles7 records
Idera Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds4 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Idera Pharmaceuticals M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Idera Pharmaceuticals
What does Idera Pharmaceuticals do?
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA- and RNA-based drug candidates. The company focuses on therapeutic applications in immune-mediated and rare diseases, and has expanded its rare-disease pipeline through its acquisition of Aceragen in 2022.
When was Idera Pharmaceuticals founded?
Idera Pharmaceuticals was founded in 1989. It employs 51 to 100 people.
Where is Idera Pharmaceuticals based?
Idera Pharmaceuticals is headquartered in Cambridge, United States, in the North America region.
Who are Idera Pharmaceuticals's main competitors?
Direct peers on record are Wave Life Sciences, ProQR Therapeutics and Aceragen. Broad incumbents are Argenx and Translate Bio (now Sanofi). Emerging players are Corbus Pharmaceuticals, Kezar Life Sciences, Dyne Therapeutics, Caballeta Bio and Avidity Biosciences.
Does Idera Pharmaceuticals have an API?
No public API is recorded for Idera Pharmaceuticals.
What industry is Idera Pharmaceuticals in?
Idera Pharmaceuticals's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAIAIAM, Rare Dermatology Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.